Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
10.1002/jms.3233 37 PoglianoJ.PoglianoN.SilvermanJ
At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits
CMS has unveiled its BALANCE model, a voluntary Medicare and Medicaid coverage pathway for GLP-1s that includes price negotiations and supplemental lifestyle support, with coverage beginning in 2026 for Medicaid and 2027 for Medicare Part D [2]
One month-therapy with a pegylated GLP-1R/GCGR dual agonists in diet-induced obese (DIO) mice resulted in bodyweight loss and improved glycemic control
US$ 28.46
US$ 23.67
US$ 28.80
US$ 25.14
US$ 29.01
US$ 24.25
US$ 29.86
US$ 27.79
US$ 20.67
